Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 47 pages report, published by Global Markets Direct

Keywords : Dementia Associated With Alzheimer's Disease Therapeutic Products under Development, Key Players in Dementia Associated With Alzheimer's Disease Therapeutics, Dementia Associated With Alzheimer's Disease Pipeline Overview, Dementia Associated With Alzheimer's Disease Pipeline, Dementia Associated With Alzheimer's Disease Pipeline Assessment

Report ThumbnailSeptember-2013
Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Dementia Associated With Alzheimer's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dementia Associated With Alzheimer's Disease. Dementia Associated With Alzheimer's Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Dementia Associated With Alzheimer's Disease.
- A review of the Dementia Associated With Alzheimer's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Dementia Associated With Alzheimer's Disease pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Dementia Associated With Alzheimer's Disease.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Dementia Associated With Alzheimer's Disease pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Dementia Associated With Alzheimer's Disease, H2 2013 7
  • Products under Development for Dementia Associated With Alzheimer's Disease - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Products under Investigation by Universities/Institutes, H2 2013 10
  • Late Stage Products, H2 2013 11
  • Mid Clinical Stage Products, H2 2013 12
  • Early Clinical Stage Products, H2 2013 13
  • Pre-Clinical Stage Products, H2 2013 14
  • Assessment by Monotherapy Products, H2 2013 23
  • Assessment by Combination Products, H2 2013 24
  • Assessment by Route of Administration, H2 2013 25
  • Assessment by Stage and Route of Administration, H2 2013 26
  • Assessment by Molecule Type, H2 2013 27
  • Assessment by Stage and Molecule Type, H2 2013 28
  • List of Tables
  • Number of Products Under Development for Dementia Associated With Alzheimer's Disease, H2 2013 7
  • Products under Development for Dementia Associated With Alzheimer's Disease - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Number of Products under Investigation by Universities/Institutes, H2 2013 10
  • Comparative Analysis by Late Stage Development, H2 2013 11
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 12
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 13
  • Comparative Analysis by Pre-Clinical Stage Development, H2 2013 14
  • Products under Development by Companies, H2 2013 15
  • Products under Investigation by Universities/Institutes, H2 2013 16
  • Kowa Company, Ltd., H2 2013 17
  • MediPost Co., Ltd., H2 2013 18
  • DiaMedica Inc., H2 2013 19
  • e-Therapeutics plc, H2 2013 20
  • Oryzon, H2 2013 21
  • Adamas Pharmaceuticals, Inc., H2 2013 22
  • Assessment by Monotherapy Products, H2 2013 23
  • Assessment by Combination Products, H2 2013 24
  • Assessment by Stage and Route of Administration, H2 2013 26
  • Assessment by Stage and Molecule Type, H2 2013 28
  • Dementia Associated With Alzheimer's Disease Therapeutics - Drug Profile Updates 40
  • Dementia Associated With Alzheimer's Disease Therapeutics - Discontinued Products 41
  • Dementia Associated With Alzheimer's Disease Therapeutics - Dormant Products 42
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Dementia Associated With Alzheimer's Disease Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Dementia Associated With Alzheimer's Disease 7
  • Dementia Associated With Alzheimer's Disease Therapeutics under Development by Companies 9
  • Dementia Associated With Alzheimer's Disease Therapeutics under Investigation by Universities/Institutes 10
  • Late Stage Products 11
  • Comparative Analysis 11
  • Mid Clinical Stage Products 12
  • Comparative Analysis 12
  • Early Clinical Stage Products 13
  • Comparative Analysis 13
  • Pre-Clinical Stage Products 14
  • Comparative Analysis 14
  • Dementia Associated With Alzheimer's Disease Therapeutics - Products under Development by Companies 15
  • Dementia Associated With Alzheimer's Disease Therapeutics - Products under Investigation by Universities/Institutes 16
  • Companies Involved in Dementia Associated With Alzheimer's Disease Therapeutics Development 17
  • Kowa Company, Ltd. 17
  • MediPost Co., Ltd. 18
  • DiaMedica Inc. 19
  • e-Therapeutics plc 20
  • Oryzon 21
  • Adamas Pharmaceuticals, Inc. 22
  • Dementia Associated With Alzheimer's Disease - Therapeutics Assessment 23
  • Assessment by Monotherapy Products 23
  • Assessment by Combination Products 24
  • Assessment by Route of Administration 25
  • Assessment by Molecule Type 27
  • Drug Profiles 29
  • Neurostem - Drug Profile 29
  • Product Description 29
  • Mechanism of Action 29
  • R&D Progress 29
  • ETX-6765 - Drug Profile 31
  • Product Description 31
  • Mechanism of Action 31
  • R&D Progress 31
  • K-828-AB - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • (memantine hydrochloride ER+ donepezil hydrochloride) - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • TAK-070 - Drug Profile 34
  • Product Description 34
  • Mechanism of Action 34
  • R&D Progress 34
  • erlotinib - Drug Profile 35
  • Product Description 35
  • Mechanism of Action 35
  • R&D Progress 35
  • gefitinib - Drug Profile 36
  • Product Description 36
  • Mechanism of Action 36
  • R&D Progress 36
  • deferoxamine - Drug Profile 37
  • Product Description 37
  • Mechanism of Action 37
  • R&D Progress 37
  • OG-635 - Drug Profile 39
  • Product Description 39
  • Mechanism of Action 39
  • R&D Progress 39
  • Dementia Associated With Alzheimer's Disease Therapeutics - Drug Profile Updates 40
  • Dementia Associated With Alzheimer's Disease Therapeutics - Discontinued Products 41
  • Dementia Associated With Alzheimer's Disease Therapeutics - Dormant Products 42
  • Dementia Associated With Alzheimer's Disease - Product Development Milestones 43
  • Featured News & Press Releases 43
  • Jun 13, 2013: Forest Labs Announces US Availability Of New Once-daily Namenda XR 43
  • Oct 26, 2012: New Research Demonstrates Potential Of IRX4204 For Reduction Of Dementia In Animal Models Of Alzheimer's And Parkinson's Disease 43
  • May 15, 2012: Adamas Announces Successful End-Of-Phase II Meeting With FDA For Arimenda 44
  • Jun 03, 2011: IQWiG Recognizes Benefits Of Memantine 44
  • Appendix 46
  • Methodology 46
  • Coverage 46
  • Secondary Research 46
  • Primary Research 46
  • Expert Panel Validation 46
  • Contact Us 47
  • Disclaimer 4

Please select a license type

Share

Related Products

Global Markets DirectDementia Associated With Alzheimer's Disease - Pipeline Review, H2 2013Product ThumbnailDementia Associated With Alzheimer's Disease - Pipeline Review, H2 2013, Industry ReportProduct #: 113325
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved